KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Biomarin Pharmaceutical (BMRN) Other Gross PP&E Adjustments: 2009-2025

Historic Other Gross PP&E Adjustments for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Sep 2025 value amounting to $2.0 billion.

  • Biomarin Pharmaceutical's Other Gross PP&E Adjustments rose 3.82% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 billion, marking a year-over-year increase of 1.12%. This contributed to the annual value of $1.9 billion for FY2024, which is 1.18% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Other Gross PP&E Adjustments is $2.0 billion, which was up 1.35% from $2.0 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Other Gross PP&E Adjustments high stood at $2.0 billion for Q3 2025, and its period low was $1.7 billion during Q4 2021.
  • Its 3-year average for Other Gross PP&E Adjustments is $1.9 billion, with a median of $1.9 billion in 2023.
  • In the last 5 years, Biomarin Pharmaceutical's Other Gross PP&E Adjustments grew by 9.73% in 2021 and then fell by 0.39% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Other Gross PP&E Adjustments (Quarterly) stood at $1.7 billion in 2021, then rose by 7.45% to $1.8 billion in 2022, then rose by 2.83% to $1.8 billion in 2023, then climbed by 1.18% to $1.9 billion in 2024, then grew by 3.82% to $2.0 billion in 2025.
  • Its Other Gross PP&E Adjustments stands at $2.0 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $1.9 billion for Q1 2025.